A Phase II Study of GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a phase II, multicenter, open-label study to evaluate the antitumor activity,
efficacy and safety of GEN-001 in combination with avelumab as a third line (3L) or greater
line treatment which is not received the Standard of Care (SOC) for patients with PD-L1
positive advanced GC/Gastroesophageal Junction Adenocarcinoma who are not received cancer
immunotherapy regimens as mono or combination therapy.